Respiratory Syncytial Virus (RSV) in Neonates & Premature Infants

Respiratory Syncytial Virus (RSV) is a widespread, highly contagious respiratory pathogen that infects the lungs and breathing passages. While it typically causes mild, cold-like symptoms in healthy adults, it is a primary driver of severe lower respiratory tract illnesses—such as bronchiolitis and pneumonia—in young infants. It is a critical concern for neonates and premature infants, whose narrow airways and immature immune systems put them at a disproportionately high risk for respiratory failure.

Epidemiological data published in The Journal of Infectious Diseases establish RSV as the leading cause of infant hospitalization in high-income nations. The pooled annual RSV hospitalization rate among infants under one year of age is estimated at approximately 19 to 20 per 1,000 infants, rising to 26 per 1,000 for infants under six months. This translates to an estimated 80,000 to over 100,000 infant hospitalizations annually in the United States alone, representing roughly 75% of all RSV-associated hospitalizations among children under five. Globally, RSV causes substantial infant mortality, particularly in resource-limited settings.

• Prematurity: Infants born prematurely (before 35 or 29 weeks of gestational age) lack mature lungs and did not receive the full transfer of maternal antibodies during the third trimester.
• Chronological Age: Infants under three months old are the most vulnerable, accounting for nearly half of all severe hospitalizations.
• Congenital Conditions: Infants with bronchopulmonary dysplasia (chronic lung disease of prematurity) or hemodynamically significant congenital heart disease.
• Environmental Exposure: Attendance at daycare facilities, older siblings in school, and exposure to environmental tobacco smoke.

RSV infection in infants may begin with mild upper respiratory signs like congestion or a decreased appetite. However, it can progress rapidly to lower respiratory tract disease. Parents and caregivers should monitor closely for:

• Fast, shallow breathing (tachypnea).
• Visible chest retractions (the skin pulling in around the ribs and neck during breathing, indicating respiratory distress).
• Persistent coughing, wheezing, or grunting sounds.
• Flaring of the nostrils.
• Periods of apnea (pauses in breathing lasting more than 15-20 seconds).
• Lethargy, unusual irritability, or a bluish tint to the lips and skin (cyanosis).
  Warning: Immediate emergency medical attention is required if an infant exhibits signs of severe respiratory distress or struggling to breathe.

Diagnosis is typically confirmed via molecular testing, such as real-time Polymerase Chain Reaction (RT-PCR) or rapid antigen detection assays using nasopharyngeal swabs.
Because standard treatment is strictly supportive (intravenous hydration, supplemental oxygen, and mechanical ventilation if required), prevention is the clinical priority:

• Monoclonal Antibodies (Passive Immunization): Extended half-life monoclonal antibodies are recommended as a single dose for neonates and infants entering their first RSV season. For specific high-risk cohorts (e.g., premature infants with chronic lung disease), monthly doses of traditional preventative antibodies may still be utilized depending on local regulatory guidelines and seasonal parameters.
• Maternal Vaccination: Clinical evidence demonstrates that administering an approved RSV vaccine to pregnant individuals between 32 and 36 weeks of gestation may help transfer protective antibodies to the fetus, offering protection from birth.